Sepsis Diagnostics Market Worth $890 million | MarketsandMarkets Trademark

Sepsis Diagnostics Market in terms of revenue was estimated to be worth $634 million in 2024 and is poised to reach $890 million by 2029, growing at a CAGR of 7.0% from 2024 to 2029 according to a new report by MarketsandMarkets Trademark
Sepsis Diagnostics Market [https://www.marketsandmarkets.com/Market-Reports/sepsis-diagnostic-market-92673155.html?utm_source=ABnewswire&utm_medium=Paid&utm_campaign=Referral] in terms of revenue was estimated to be worth $634 million in 2024 and is poised to reach $890 million by 2029, growing at a CAGR of 7.0% from 2024 to 2029 according to a new report by MarketsandMarkets Trademark .

Factors such the commercialization and availability of a wide variety of approved sepsis diagnostic devices, rising prevalence of sepsis, incidence of hospital-acquired infections, growing number of surgical procedures and increasing geriatric population are high growth prospects for the sepsis diagnostics market during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155&utm_source=ABnewswire&utm_medium=Paid&utm_campaign=Referral]

The molecular diagnostics segment is to register a significant growth rate over the forecast period of 2024-2029.

Based on the technology, over the forecast period of 2024-2029, the molecular diagnostics segment is to register a significant growth rate. The sepsis diagnostics product market is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. The molecular diagnostics segment comprises PCR, microarray, peptide nucleic acid fluorescent in situ hybridization and DNA sequencing. The key factors encouraging the growth of mesh segment during the forecast period are the the growing need for early disease diagnosis and various advantages offered by this technique as compared others.

The hospitals & speciality clinics segment accounted for the largest share of sepsis diagnostics market in 2024-2029.

Based on end user, the hospitals & speciality clinics segment is estimated to hold the largest market share of the sepsis diagnostics market during the forecast period. Increasing number of patients hospitalized with sepsis, in-house hospital laboratories perform a large number of blood culture tests to identify the blood stream infections (BSIs caused by bacteria, fungi/yeast, or viruses) and high prevalence of sepsis coupled with a large number of fatalities caused by the illness lead to a large share of the segment.

Asia Pacific registered the highest CAGR in the market during the forecast period.

In 2024, Asia Pacific is expected to register the highest CAGR in the market for sepsis diagnostics during the forecast period. Asia Pacific comprises China, India, South Korea, Taiwan, and Singapore, and the rest of Asia Pacific. Factors such as the growing adoption of advanced treatment options, presence of a large target patient population and improving diagnosis and treatment rates are driving the growth of the APAC sepsis diagnostics market during the forecast period.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=92673155 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=92673155&utm_source=ABnewswire&utm_medium=Paid&utm_campaign=Referral]

Sepsis Diagnostics Market Dynamics:

Drivers:

* Increasing hospital-acquired infection incidences

Restraints:

* High costs of automated diagnostic devices

Opportunities:

* Rapid diagnostic/POC techniques development for early sepsis diagnosis

Challenge:

* Dearth of skilled healthcare professionals

Key Market Players of Sepsis Diagnostics Industry:

As of 2023, prominent players in sepsis diagnostics are bioMerieux (France), Becton Dickinson Company (US), Danaher Corporation (US), Abbott Laboratories (US), and Roche Diagnostics (Switzerland). Other players include T2 Biosystems (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), among others.

A breakdown of the primary participants referred to for this report is provided below:

* By Company Type: Tier 1- 25%, Tier 2- 30%, and Tier 3- 45%
* By Designation: C-level- 26%, Directors- 30%, and Others- 44%
* By Region: North America- 40%, Europe- 31%, Asia Pacific- 20%, Latin America- 6%, MEA- 3%

Recent Developments of Sepsis Diagnostics Industry:

* In April 2023, BioMerieux launched BIOFIRE FIREWORKS, an integrated software solution for BIOFIRE Systems optimizing laboratory services and supporting data-driven decisions.
* In May 2023, Sysmex Corporation launched clinical flow cytometry system Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products in Japan.
* In June 2023, T2 Biosystems collaborated with Vanderbilt University Medical Center to implement and evaluate the T2Bacteria Panel for clinical use.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=92673155 [https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=92673155&utm_source=ABnewswire&utm_medium=Paid&utm_campaign=Referral]

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=sepsis-diagnostics-market-worth-890-million-marketsandmarkets]
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.prnewswire.com/news-releases/sepsis-diagnostics-market-worth-890-million--marketsandmarkets-302110341.html



This release was published on openPR.